Patient & Visitor Alert: Because flu cases are on the rise, starting February 24, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities throughout Carolinas HealthCare System. Learn more.
Randomized, double-blind, placebo-controlled parallel group outpatient study that utilizes standard stroke rehabilitation outcome measures, as well as fMRI tecniques to evaluate the effect of study drug, monoamine oxidase Type B (MAO-B) inhibitor, HT-3951, on motor recovery and behavior in medically stable subjects following ischemic stroke.
Who may be Eligible
Medically and neurologically stable male and female subjects 40-85 years of age. Subjects with mild to moderate, unilateral upper extremity motor impairment with =2 and =6 weeks post stroke acute subjects, and between >6 and =24 weeks post-stroke chronic subjects, and will initiate, or are scheduled to undergo, simultaneous standardized upper limb rehabilitation under the supervision of a licensed therapist at least 2 weeks before Day 1.